Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.59 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109767 | 0.91 | FABP4 (0.85) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL7841736 | 0.87 | FABP4 (0.85) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL27681709 | 0.87 | FABP4 (0.85) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL29622832 | 0.87 | FABP4 (0.92) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL25828 | 0.87 | FABP4 (0.92) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8052123 | 0.86 | MEN1 (0.58) | FABP4AKR1C3AKR1C2PTGS1NPC1 | |
| Fenamic Acid SCHEMBL27925717 | 0.85 | FABP4 (0.82) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL10800939 | 0.85 | FABP4 (0.89) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL3657701 | 0.85 | FABP4 (0.89) | FABP4AKR1C3AKR1C2PTGS1MEN1 | |
| Fenamic Acid SCHEMBL28520019 | 0.85 | FABP4 (0.89) | FABP4AKR1C3AKR1C2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105412108-A | Application of 2-methoxy-9-acridine(4-methoxybenzamido) thiourea to preparing of acetylcholin esterase inhibitor | UNIV GUANGXI CHINESE MEDICINE | 2016-03-23 | — | — | CN | claimed |
| US-4921875-A | Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | claimed |
| WO-2024035268-A2 | TAU PATHWAY MODULATORS | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2024-02-15 | — | — | WO | disclosed |
| CN-113683615-A | Evodiamine derivative and preparation and application thereof | 南华大学 | 2021-11-23 | — | — | CN | disclosed |
| EP-3315028-B1 | USE OF INHIBITORS OF NLP PROTEINS AS PHYTOPHARMACEUTICALS FOR PLANT PATHOGEN CONTROL | KEMIJSKI INST (SI) | 2020-09-02 | — | — | EP | disclosed |
| EP-3315028-B1 | USE OF INHIBITORS OF NLP PROTEINS AS PHYTOPHARMACEUTICALS FOR PLANT PATHOGEN CONTROL | KEMIJSKI INST (SI) | 2020-09-02 | — | — | EP | disclosed |
| CN-105412108-B | 2- methoxyl group -9- acridines（To methoxy benzamide base）Application of the thiocarbamide in acetylcholinesterase inhibitor is prepared | 广西中医药大学 | 2018-07-10 | — | — | CN | disclosed |
| CN-105476992-B | Application of the 2- methoxyl group -9- acridine benzamido thiocarbamides in acetylcholinesterase inhibitor is prepared | 广西中医药大学 | 2018-07-06 | — | — | CN | disclosed |
| EP-3315028-A1 | INHIBITORS OF NLP PROTEINS AS PHYTOPHARMACEUTICALS FOR PLANT PATHOGEN CONTROL | Kemijski Institut (SI) | 2018-05-02 | — | — | EP | disclosed |
| EP-3315028-A1 | INHIBITORS OF NLP PROTEINS AS PHYTOPHARMACEUTICALS FOR PLANT PATHOGEN CONTROL | Kemijski Institut (SI) | 2018-05-02 | — | — | EP | disclosed |
| CN-105399726-B | 2 methyl, 9 acridine（P-methylphenyl）1,2,3 triazoles and its preparation method and application | 广西中医药大学 | 2018-04-17 | — | — | CN | disclosed |
| CN-104326979-B | 2-methyl-9-acridine (to methoxy benzamide base) thiocarbamide and its production and use | GUANGXI UNIVERSITY OF CHINESE MEDICINE (CN) | 2015-12-30 | — | — | CN | disclosed |
| CN-104326979-A | 2-methyl-9-acridine(p-methoxy benzamido)thiourea, preparation method and uses thereof | UNIV GUANGXI CHINESE MEDICINE | 2015-02-04 | — | — | CN | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-0270091-B1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS OF THERAPEUTIC VALUE, AND INTERMEDIATES FORMED DURING SAID PROCESSES | TANABE SEIYAKU CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
| US-5053417-A | Antiulcer agents | TANABE SEIYAKU CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-5002945-A | Antiulcer agents | TANABE SEIYAKU CO. LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| US-4996217-A | Antiulcer agents | TANABE SEIYAKU COMPANY, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| EP-0270091-A1 | Imidazole derivatives, processes for the preparation of the same, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments of therapeutic value, and intermediates formed during said processes | TANABE SEIYAKU CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | CLIC1, ASIC1, CLIC4 | FABP4 1600/4885AKR1C3 787/4885AKR1C2 477/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | FABP4 501/4885AKR1C3 1497/4885AKR1C2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.